BEVERLY, MA--(Marketwire - December 14, 2012) - Cellceutix Corporation (OTCBB: CTIX) (the Company), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that clinical trials being hosted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Ce